Brain Cancer

Published Date : Oct 2023
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

"Recognizing the Obstacles of Brain Cancer: Obtaining Life-Changing Benefits and Evaluating the Market Structure"

Brain Cancer Epidemiology Overview -

Brain cancer, a devastating and often life-threatening disease, imposes a significant burden on individuals and healthcare systems worldwide. Its complexity, coupled with the brain's vital role in controlling our bodily functions, makes it a formidable adversary. A brain tumor is a mass of abnormal cells that is developing either inside or outside of the brain. Spinal tumors and brain tumors are both referred to as Central Nervous System (CNS) cancers. Malignant (cancerous) or benign (non-cancerous) brain tumors are both possible. While some tumors grow immediately, others grow so slowly.

Among all brain tumors, only around one-third are malignant. Brain tumors affect brain function and health whether they are cancerous if they enlarge to a level where they press against nearby nerves, blood vessels, or tissue. Brain tumors that develop promptly are often referred to as primary cancer. Secondary cancer, also known as metastatic brain tumors, are cancer that develops in one place of the body before spreading to another, usually the brain.

According to estimates from the Global Cancer Observatory (GLOBOCAN) for 2020, brain and central nervous system cancer make up a sizeable portion of the global disease burden, coming in at 19th among the most common malignancies (1.9% of all cancers) and 12th among the top reasons for cancer deaths (2.5% of all cancers). Therefore, identifying brain cancer in its earliest stages is crucial since it enables more efficient treatment plans and raises survival rates.

Additionally, the National Brain Tumor Society states that there are more than 120 different forms of brain cancer, some of which, like glioblastoma, are malignant and spread quickly. Meningioma is an example of a benign, slow-growing kind of brain tumor.

Tumors make up all forms of brain cancer, although not all tumors in the brain are malignant. For instance, glioblastomas, a particularly deadly type of brain cancer, are detected in more than half of all adult cases of gliomas. Malignant brain tumors include oligodendrogliomas and ependymomas as well.

For this reason, it's difficult to obtain a thorough and accurate diagnosis of a brain tumor. Furthermore, it's critical to realize that even benign tumors harm brain cells and result in side effects like headaches, exhaustion, and double or blurred vision. Therefore, timely and effective treatment is essential to general health even if a brain tumor is not malignant.

Depending on the size and location of the brain tumor, specific signs and symptoms are present. The severity of the symptoms can also be influenced by the tumor grade, another term for the rate of growth of the brain tumor. Individuals get a brain tumor at any age. However, the risk of getting most malignancies, including brain tumors, rises with age.

Malignant tumors are the most common kind of brain cancer in adults. Gliomas make up around 78% of malignant primary brain tumors. Primitive neuroectodermal tumors (PNETs), which are most frequently found in children and typically grow quickly, are tumors that form in glial cells, which surround and support nerve cells. However, they may also impact adults.

Ages 85 to 89 are the most at risk for developing brain tumors. Being overweight or obese raises the risk of developing some cancers, including meningiomas, a kind of brain tumor. Being overweight or obese contributes to about 2 out of every 100 cases of brain cancer (2%), which are identified each year in the UK.

Cancer of the nervous system, which includes the brain, ranks as the tenth leading cause of mortality in both sexes. A total of 347,992 new cases of brain cancer were recorded globally in 2019. Brain cancer was diagnosed in 187,491 (54%) males and 160,501 (46%) women. WHO studies show that in 2019, the incidence and mortality rates for brain cancer varied between men and women, with men at higher risk of developing the cancer.

Moreover, the Western Pacific was reported to have the highest incidence and death of brain cancer in both sexes combined aged 0–14 years, whereas Africa had the lowest rates. Incidence and mortality rates for brain cancer among males and females combined aged 15 and older were highest in Europe in 2019 and lowest in Africa. According to the WHO, a total of 246,253 fatalities from brain cancer were reported globally in 2019 (138,605 men and 107,648 women).

Therefore, early management improves the quality of life for patients by reducing the neurological, cognitive, and physical deficits brought on by brain tumors. It is impossible to ignore the significance of the research, education, and prompt diagnosis in the fight against this difficult illness, which ultimately holds the promise of better results and more promising futures for people who are impacted by brain cancer.

Thus, DiseaseLandscape Insights is there to support those who are involved in the industry by offering data about the Brain Disease market. Our team assists them in making informed choices in healthcare equipment, therapies, and diagnostic methods, as well as details about novel technologies and innovations in brain cancer and encouraging higher expansion in an industry.

Diagnostic Analysis -

"Brain Cancer Diagnostic Innovations: Assessing It Before It Emerges."

Diagnosing brain cancer often involves a multi-disciplinary approach, with input from neurologists, neurosurgeons, oncologists, radiologists, and pathologists. Early and accurate diagnosis is crucial for determining the appropriate treatment strategy for brain cancer.

Diagnosing brain cancer involves a combination of diagnostic methods, including laboratory tests, imaging studies, physical examinations, and, in some cases, biopsies. Here are the different diagnostic methods used to detect brain cancer:

  1. Physical Examination and Medical History

Only 5% to 10% of individuals who have brain tumors have a family history of the disease. To evaluate reflexes, muscle power, coordination, sensory perception, and other neurological functions, a full neurological examination is carried out.

  1. Laboratory Tests:
  • Blood Tests: Blood tests do not directly diagnose brain cancer, but they can help to rule out other medical conditions and provide information about the patient's overall health.
  • Cerebrospinal Fluid (CSF) Analysis: A lumbar puncture (spinal tap) can be performed to collect and analyze CSF. Elevated levels of certain markers may suggest the presence of brain tumors.
  1. Imaging Studies
  • Brain MRI or CT scan: The most accurate imaging procedure for detecting brain cancers is magnetic resonance imaging (MRI). The location, size, and features of brain tumors can be identified via MRI scans, which produce comprehensive images of the brain.

Digital tomography Cross-sectional images of the brain are produced by CT scans using X-rays. They are frequently used for preliminary screening and to determine the density of the tumor. For patients who are unable to have an MRI, a CT scan is a useful alternative. A contrast chemical, which makes the tumor easier to see during these tests, is injected into one of the veins beforehand. The size and precise location of the tumor are revealed by these tests in great detail. Additionally, healthcare professionals may examine patients' lungs, colon, or breasts among other bodily areas.

  • Positron Emission Tomography (PET) Scan and Electroencephalogram (EEG)

Healthcare Providers use advanced scanners like PET scans that show areas of increased metabolic activity in the brain, helping to distinguish between tumor tissue and healthy tissue. Additionally, EEG records electrical activity in the brain and is used to detect abnormalities in brain function, which result from a tumor or seizures.

  1. Biopsy

To determine the type of brain cancer and if it is cancerous, medical professionals typically need to perform a biopsy of the tumor (removal of a sample of the tumor for inspection under a microscope). A biopsy is carried out by a neurosurgeon when the tumor is being surgically removed whole or in part. They can also do a stereotactic biopsy, which entails drilling a tiny hole in the patient's skull and inserting a needle to extract a sample of tumor tissue, if the tumor is hard to reach. The most accurate technique for detecting brain cancer is this one. In rare circumstances, a biopsy may be done to access and sample the tumor without major surgery using a needle guided by imaging methods, such as CT or MRI.

Spinal tap (lumbar puncture)

For this procedure, the healthcare provider uses a small needle to remove cerebrospinal fluid (CSF) from around the spine. This fluid is examined in a lab to check for cancerous cells. When doctors have reason to believe that the tumor has spread to the meninges, the tissues that cover your brain, they perform this treatment.

  1. Specialized tests /Functional Tests:

Certain tests sometimes help with the diagnosis. For example, healthcare providers may order tests that check patients' blood and cerebrospinal fluid for substances that certain tumors release called tumor markers. They also test for gene abnormalities that are characteristic of certain tumors

  • Functional MRI (fMRI): fMRI maps brain activity by measuring changes in blood flow. It helps determine the tumor's location in relation to critical brain areas responsible for functions like speech and movement.
  • Neuropsychological Testing: These tests assess cognitive function, memory, and other mental abilities to evaluate the impact of a brain tumor on a patient's brain function.
  • Genetic and Molecular Testing: Genetic and molecular profiling of tumor tissue provides insights into the tumor's genetic mutations and characteristics. This information guides treatment decisions, especially in cases of glioblastoma and other aggressive brain cancers

The below table provides names of the market competitors who are transforming healthcare with advanced diagnostic breakthroughs, are listed below,

                                                                          Diagnostic Market Players for Brain Cancer

Imaging Studies


Functional Test Neuropsychological, Genetic, and Molecular Testing

PET Scan Equipment and EEG Equipment

Shimadzu Medical Systems

(GE) Healthcare

Roche Diagnostics

Bruker Corporation

Fujifilm Medical Systems

Siemens Healthineers

Siemens Healthineers

Philips Healthcare

Hologic, Inc

Canon Medical Systems

Abbott Diagnostics

GE Healthcare

Samsung Healthcare

Varian Medical Systems

Thermo Fisher Scientific

Siemens Healthineers


Hitachi Healthcare


Illumina, Inc

Bruker Corporation

Hitachi Healthcare



Natus Medical Incorporated

Canon Medical Systems Corporation


Bio-Rad Laboratories


Philips Healthcare


Agilent Technologies


GE Healthcare




Siemens Healthineers






Imaging Studies


Functional Test Neuropsychological and Genetic and Molecular Testing

PET Scan Equipment and EEG Equipment

Trinias angiography systems

LOGIQ E10 Ultrasound System

Cobas 6000 Analyzer Series

Biograph PET/CT scanners

FCT Embrace CT Scanner

SOMATOM Force CT Scanner

Atellica Solution

Discovery PET/CT scanners

Brevera Breast Biopsy System

Edge Radiosurgery System


Vereos PET/CT

Echelon MRI Systems,

Oasis Open MRI System

Ion Torrent Genexus System

Celesteion PET/CT scanner

Supria CT Scanners

O-arm Surgical Imaging System

NextSeq 550 System


RS85 Prestige Ultrasound System


QIAsymphony SP/AS

Nicolet EEG systems

Ingenia MRI Systems


Bio-Plex Suspension Array System


Ingenuity CT Scanners


SureSelectXT Target Enrichment System







Leaders in the industry gain assistance from DiseaseLandscape Insights in the development of various diagnostic kits. Also, the application of cutting-edge technology to enhance current diagnostic procedures, and the provision of information on current market participants and their offerings to understand market dynamics.

Treatment Analysis -

"Treatment Innovations: An Approach for a Healthier Life"

Treatment for brain cancer varies depending on the type and stage of the cancer, as well as the patient's overall health and individual circumstances. Brain cancer treatment may involve a combination of therapies. Here are different treatments commonly used to treat brain cancer:

  1. Surgery

Surgical removal of the brain tumor is often the first-line treatment if possible. The goal is to remove as much of the tumor as safely achievable. In some cases, a biopsy is performed to determine the tumor type before planning further treatment.

While some tumors can be safely removed due to their position, others may only be able to be removed in part due to their location. Brain cancer benefits from even partial removal. Clinically dangerous benign tumors are also surgically removed. Surgery can be combined with other treatments, such as radiation therapy and chemotherapy.

  1. Radiation Therapy

For tumors of the brain and spinal cord, radiotherapy is frequently used as treatment. To eliminate cancer cells, high-energy X-rays are used. Patients with tumors of the brain or spinal cord typically get external radiation. This entails destroying the cancer using radiation from a machine. External radiation comes in a variety of forms. The most typical kind is known as conformal radiotherapy.

High-energy X-rays or protons are used in radiation therapy to target and eliminate cancer cells that are present in the brain. Since it can be given before or after surgery, as well as for palliative care, external beam radiation treatment is frequently utilized for brain cancer. Stereotactic radiosurgery, which uses tools like the Gamma Knife and the CyberKnife to target specific areas of the body, is another type of radiation therapy.

  1. Chemotherapy

Chemotherapy uses medication to either kill or slow the growth of cancer cells. There are two types of chemotherapy: systemic chemotherapy, which is frequently injected into the circulation and used to treat some forms of brain cancer. Targeting cancer cells in the brain and spinal cord, intrathecal chemotherapy involves injecting chemotherapy medications directly into the cerebrospinal fluid.

After treatment, brain tumors may (recur) or continue to advance. Depending on the circumstance, the location of the tumor, and previous treatments, there are many therapeutic options for recurring brain tumors. It could involve chemotherapy administered either orally or intravenously. Targeted therapy may also be used, such as the medication bevacizumab, which prevents cancer cells from growing.

  1. Targeted Therapy

Targeted therapies are drugs that target specific molecules or pathways involved in the growth of cancer cells. They are used for some types of brain cancer, particularly when specific genetic mutations or biomarkers are present. Examples include bevacizumab (Avastin) and temozolomide (Temodar).

  • EGFR Inhibitors: Epidermal Growth Factor Receptor (EGFR) inhibitors like gefitinib and erlotinib are being investigated for glioblastoma, a type of brain cancer.
  • ALK Inhibitors: Anaplastic Lymphoma Kinase (ALK) inhibitors like crizotinib are explored for certain brain tumors, such as anaplastic oligodendroglioma
  • Angiogenesis Inhibitors: These drugs target the growth of blood vessels that feed tumors. Bevacizumab is an example and is used in certain cases of glioblastoma.
  1. Corticosteroids

Is a type of treatment that helps patients to reduce pain after surgery and helps in a faster healing process. Corticosteroids like dexamethasone are used to reduce swelling and manage symptoms like edema (fluid buildup) around brain tumors. This majorly includes physical therapy, speech therapy, and counseling. One can recover from neurosurgery with the aid of physical therapy, occupational therapy, and speech therapy.

Different Treatment options for brain cancer are highly individualized, and the choice of treatment depends on factors such as the tumor type, location, size, and the patient's overall health. Multidisciplinary teams of healthcare professionals, including neurosurgeons, oncologists, radiation therapists, and supportive care specialists, collaborate to develop the most appropriate treatment strategy for each patient.

Emerging Treatments -

Emerging treatments for brain cancer are continually being explored as researchers seek more effective and targeted therapies.

  1. Immunotherapy:

Immune Checkpoint Inhibitor Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) are being studied in clinical trials for certain types of brain cancer. These inhibitors work by blocking immune checkpoint proteins to unleash the body's immune response against cancer cells.

Talimogene Laherparepvec (T-VEC) is an oncolytic herpes simplex virus that's injected directly into brain tumors, where it replicates and destroys cancer cells. It's primarily used for melanoma brain metastases.

  1. Gene Therapy: CAR-T Cell Therapy and Stem Cell Therapies

Chimeric Antigen Receptor T-cell (CAR-T) therapy is being explored as a treatment for brain cancers. CAR-T cells are engineered to target specific antigens in cancer cells. Stem cell-based approaches, including neural stem cells, are being studied for their potential in brain cancer treatment and tissue regeneration.

We at DiseaseLandscape Insights help clients and market participants in the brain cancer market to stay stronger and ahead of the competition by doing in-depth analyses of treatment alternatives, new innovations, and technology.

DLI also provides substantial assistance in the planning, execution, and evaluation of clinical studies for novel medication development.

Below is the list of the market leaders who are transforming the landscape and encouraging innovation in the search for better health outcomes along with the names of their various brain cancer treatment products.

                                                                          Market Players for Treatment of Brain Cancer

Surgical Instruments

Target Therapy Drugs


Radiation Therapy

Medtronic plc


Bayer AG

Varian Medical Systems

Integra LifeSciences Corporation

Tocagen Inc

Merck & Co., Inc

Siemens Healthineers

Stryker Corporation

Eisai Pharmaceuticals

Eli Lilly

Elekta AB

Carl Zeiss Meditec AG


Bristol Myers Squibb

Brainlab AG

NICO Corporation


Novartis AG

Mevion Medical Systems

Codman Neuro

Bristol Myers Squibb


ViewRay Inc

Misonix, Inc.


Sun Pharmaceutical Industries Ltd

Sumitomo Heavy Industries, Ltd

Brainlab AG



Ion Beam Applications S.A.



Surgical Instruments

Target Therapy Drugs



OPMI PENTERO 900® Surgical Microscope

Avastin (bevacizumab)


TrueBeam™ Radiotherapy System

KINEVO® 900 Visualization System

Temodar (temozolomide)


Elekta Infinity™

BrainPath® Access System

Opdivo (nivolumab)


CyberKnife® System

Codman® Neuro line

Afinitor (everolimus)


Novalis Radiosurgery

SonicOne® Ultrasonic Surgical System

Somatuline Depot (lanreotide)


ARTISTE™ Solution

Airo® Mobile Intraoperative CT

Lenvima (lenvatinib)


Radiance 330® Proton Therapy System

Sonopet® Ultrasonic Aspirator

Toca 511 & Toca FC


MEVION S250™ Proton Therapy System

LICOX® Brain Tissue Oxygen Monitoring System



MRIdian® Linac

Midas Rex® High-Speed Drills




CUSA® Excel+ Ultrasonic Aspirator:





Market Trends Analysis -

"Identifying the Developmental Trends across the Market for Brain Cancer"

The field of brain cancer research and treatment is witnessing several noteworthy market trends. Firstly, there is an increasing emphasis on precision medicine and personalized treatment approaches. Advances in genetic profiling and molecular diagnostics are enabling healthcare providers to tailor therapies to the specific characteristics of a patient's tumor. This trend is improving treatment outcomes and minimizing the use of one-size-fits-all approaches.

Second, immunotherapy is becoming more popular in the management of brain cancer. Immune checkpoint inhibitors face difficulties crossing the blood-brain barrier, but new strategies are being investigated in ongoing research to use the immune system's ability to fight brain tumors. This involves the creation of vaccinations and the promising CAR-T cell treatments that have shown promise in clinical studies.

A crucial component of the fight against brain cancer is early identification. There are now significant opportunities for detecting brain cancers in their earliest, most curable stages due to recent advancements in this field. Analyzing biomarkers in blood or cerebrospinal fluid is a component of liquid biopsies, a fast-developing science. These non-invasive tests identify brain cancer-related mutations and help with early detection and treatment response tracking.

Additionally, improvements in neuroimaging methods are improving the efficiency of early detection. Modern radionics and artificial intelligence algorithms, along with cutting-edge MRI and PET scans, enable more accurate detection of small cancers and subtle alterations in brain tissue. Additionally, AI algorithms are being used to forecast illness progression and therapy outcomes, which helps with treatment planning.

Market trends in brain cancer underscore the importance of these advancements that hold the potential to improve patient outcomes and quality of life. Meanwhile, developments in early detection methods, including liquid biopsies and advanced neuroimaging, are offering hope for identifying brain tumors at their earliest stages, ultimately leading to more effective treatments and better prognoses for patients.

DiseaseLandscape Insights helps the industry player in the brain cancer disease market by providing intense knowledge about all the existing market players, their innovations, strategies, and collaborations and helps select the correct marketplace to grow exponentially

Competitive Analysis -

"Determining the shifting Patterns to Stay Competitive, within the Industry of Brain Cancer."

The brain cancer market is characterized by intense competition among pharmaceutical companies, research institutions, and medical device manufacturers. These entities strive to develop innovative therapies, diagnostic tools, and treatment modalities to improve patient outcomes in the face of this formidable disease.

Major pharmaceutical players, including Roche, Pfizer, Novartis, and Bristol-Myers Squibb, are actively engaged in brain cancer research and drug development. These companies have a strong focus on precision medicine, aiming to develop targeted therapies that can effectively combat various types of brain tumors.

For example, Roche's Avastin (bevacizumab) has been used to treat recurrent glioblastoma, demonstrating the potential of anti-angiogenic drugs in brain cancer management. The pursuit of immunotherapies is also a significant area of competition, with companies exploring checkpoint inhibitors and CAR-T cell therapies tailored to brain cancer patients.

Leading research institutions like Dana-Farber Cancer Institute and MD Anderson Cancer Center are instrumental in advancing brain cancer treatment. They conduct extensive clinical trials, contribute to scientific breakthroughs, and collaborate with pharmaceutical companies to develop new therapies. These institutions play a crucial role in testing novel treatments and diagnostic tools, bridging the gap between laboratory discoveries and clinical practice.

The treatment of brain cancer greatly benefits from the work of companies that specialize in medical equipment. For instance, Elekta and Varian manufacture sophisticated radiation therapy systems, such as platforms for intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery. By enabling precise and focused radiation administration, these technologies reduce the risk of damaging healthy brain tissue. This market's rivalry aims to lessen adverse effects while improving radiation therapy's accuracy and efficacy.

The competitive landscape in brain cancer continues to evolve with a focus on targeted therapies, immunotherapies, and precision medicine. Advances in diagnostics and treatment technologies, including AI and gene therapies, hold the potential to transform the market. Collaborations and partnerships will likely play a crucial role in driving innovation and improving outcomes for brain cancer patients

The services offered by DiseaseLandscape Insight assist the market participants by offering in-depth knowledge about all the players in the market, their innovations, strategies, and collaborations, and assistance in choosing the best market to develop exponentially.

Regulatory Framework Analysis -

The regulatory framework governing the brain cancer market is critical in ensuring the safety and efficacy of treatments, as well as fostering innovation in this challenging field. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others worldwide play a central role in evaluating and approving products for brain cancer treatment.

These regulatory agencies assess the safety and effectiveness of new drugs, biologics, medical devices, and therapies through rigorous clinical trials and pre-market evaluations. Notably, the brain cancer market has seen some key approvals for products in recent years, contributing to the advancement of treatment options.

For instance, the FDA approved the use of temozolomide and bevacizumab together in 2019 for the treatment of patients with newly diagnosed glioblastoma (GBM). This approval aims to give this aggressive type of brain cancer a more potent therapeutic alternative.

Furthermore, advancements in diagnostic tools and imaging technologies, such as advanced MRI and PET scans, have been granted regulatory approval. These tools enhance the precision of brain cancer diagnosis and treatment planning, aiding healthcare providers in delivering more effective and targeted therapies.

The FDA granted Tafinlar (dabrafenib) and Mekinist (trametinib) rapid approval in 2020 for the treatment of BRAF V600E-mutant metastatic non-small cell lung cancer, which can develop brain tumors.

Due to its effect on brain amyloid beta plaques, the FDA approved the immunotherapy medicine Aduhelm (aducanumab) for Alzheimer's disease in 2021. The drug also has significance for brain cancer studies.

In the rapidly evolving landscape of brain cancer research and treatment, regulatory frameworks and approvals continue to be instrumental. They ensure that innovative therapies and technologies reach patients, ultimately improving outcomes and quality of life for individuals facing the challenges of brain cancer.

Ongoing collaboration between regulatory authorities, pharmaceutical companies, and research institutions is essential to drive progress in this critical area of healthcare.

Thus, Disease Landscape Insights provides data-driven insights to involved market players that guide in international collaboration, risk assessment, regulation formulation, surveillance, and monitoring of research as well as emergency response preparation.

By utilizing data from DiseaseLandscape Insights, institutions, and market participants effectively control, and respond to cancerous outbreaks while ensuring that the impacted populations are safe and well-cared for.

Clinical Assessments -

Here, DiseaseLandscape Insights continues the exciting journey into the field of brain cancer treatment, where remarkable innovative opportunities and novel developments will change the way diseases are treated. DiseaseLandscape Insights makes it easy to establish and implement clinical trials for novel treatments and drugs, patient recruitment tactics, regulatory compliance, and assuring favorable trial outcomes. These are all made easier with the assistance of DiseaseLandscape Insights.

The below table shows the study titles of the currently ongoing clinical trials, together with the phases in which they are currently being done.

Phase 1

Phase 2

Phase 3

Phase 4

Joan Ribas Araquistain Program for Research and Therapeutic Innovation in Prehabilitation, Rehabilitation and Comprehensive Approach to the Sequelae of Brain Tumors

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation with Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology

A Randomized Pivotal Study Assessing the Efficacy of Targeted Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases


A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants with MET Alterations and Brain Tumors

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Pre-Operative vs. Post-Operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Targeting Pediatric Brain Tumors with Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i)

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors

Comparison of the Analgesic Effects of Scalp Nerve Block and Intravenous Ibuprofen Applications Under the Guidance of Nociception Level Index (NoL) in Patients Undergoing Elective Supratentorial Craniotomy

A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics &Preliminary Anti-Cancer Efficacy of ABM-1310 in Patients with BRAF V600-Mutant Relapsed &Drug Resistant Primary Malignant Brain Tumors

An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy, and PK of HLX208 for Refractory Primary Brain Tumors with BRAF Mutation

Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Medulloblastoma Patients

A Pilot Study of Dual Time Point FDG PET MR Imaging Optimization for the Evaluation of Brain Metastasis

Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children with Recurrent/Refractory Malignant Brain Tumors

Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents with Supratentorial Brain Tumors

A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM)

PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials

Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib with Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients with Brain Cancer

A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors

A Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases

A Prospective, Randomized Controlled Study to Compare the Effect of Sevoflurane and Propofol for Maintenance of Anesthesia on Postoperative Recovery After Transsphenoidal Resection of Pituitary Adenoma



The information provided by DiseaseLandscape Insights (DLI) is essential, particularly in the fight against brain cancer. DiseaseLandscape Insights offers a wide range of services that aim to help the healthcare industry, its professionals, researchers, and industry players in improving patient outcomes and promoting company growth and expansion.

The DLI services provide valuable data on the most recent developments, therapeutic approaches, and developing trends in the management of brain cancer by using the resources of extensive market research. These insights enable healthcare providers to establish targeted strategies, make informed decisions, and offer patients individualized care. Additionally, our services serve as a catalyst for innovation and cooperation, encouraging collaborations between industry players and researchers to advance the diagnosis, treatment, and prevention of brain cancer.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape